Press Release, July 2019

A second study is just published in the renowned scientific journal ACS Nano. This is a continuation of the former study, where the research group already showed that the indigenous biomaterial hyaluronic acid (HA) can be efficiently developed into nanoparticles, offering a highly biocompatible delivery platform for targeted imaging and precision therapy of atherosclerosis. In this new study, that was co-funded by Sensi Pharma, a next step was taken to better understand the details of the trafficking of these HA nanoparticles into the atherosclerotic plaque. A better comprehension of the characteristics of this platform will aid in the application of endo-cannnabinoid based nanoparticles in research, such as the recently started NAVISTROKE research program, and eventually the clinic.

As described in the former ACS Nano publication the research group used HA nanoparticles to target atherosclerotic plaques in experimental models. They showed that this nanoparticle platform offers beneficial characteristics for the accurate and efficient delivery of therapeutic and diagnostic compounds, including cannabinoids and related ligands, to atherosclerotic lesions. This was a result of favourable pharmacokinetics, cost effectiveness and the high affinity of these nanoparticles for immune cells within the atherosclerotic plaque.

Read the full press release here.